Galapagos NV's service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca, under which BioFocus will perform medicinal chemistry, computational chemistry and support biology and ADMET services for AZ's infection discovery program based in Boston. Total contract value for Galapagos will be $938,000.
This is the third collaboration between the two companies since August 2006. BioFocus DPI is also providing chemistry and supporting biology and ADME services for an AZ hit-to-lead program.
"We now have a global relationship with AstraZeneca, working with several sites based in Europe and the U.S.," said Galapagos' chief executive officer, Onno van de Stolpe. "This type of expansion fits very well with our strategy for growth of the BioFocus DPI service division."
"Our European colleagues have been pleased with the progress of the drug discovery programs ongoing with BioFocus DPI. The decision for our U.S.-based R&D to enter into this collaboration with BioFocus DPI is based on this productivity and the good working relationship between the two companies thus far," added Trevor Trust, vice president - Infection Discovery at AstraZeneca U.S.